Alamar Biosciences Sets IPO at 9.4 Million Shares Priced at $15-$17 Each

Dow Jones

04/16

By Colin Kellaher

Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering.

At the $16 midpoint of that range, the Fremont, Calif., proteomics company said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares.

Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint.

The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 16, 2026 10:41 ET (14:41 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2627211129"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627211129\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627211129?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627211129","market":"nz","top_or_hot":-1,"title":"Alamar Biosciences Sets IPO at 9.4 Million Shares Priced at $15-$17 Each","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering. \n</p>\n<p>\n  At the $16 midpoint of that range, the Fremont, Calif., proteomics company  said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares. \n</p>\n<p>\n  Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint. \n</p>\n<p>\n  The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2026 10:41 ET (14:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alamar Biosciences Sets IPO at 9.4 Million Shares Priced at $15-$17 Each</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlamar Biosciences Sets IPO at 9.4 Million Shares Priced at $15-$17 Each\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-04-16 22:41</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering. \n</p>\n<p>\n  At the $16 midpoint of that range, the Fremont, Calif., proteomics company  said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares. \n</p>\n<p>\n  Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint. \n</p>\n<p>\n  The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2026 10:41 ET (14:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALMR","symbol_name":"Alamar Biosciences, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2627211129","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627211129","pubTimestamp":1776350460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering.At the $16 midpoint of that range, the Fremont, Calif., proteomics company  said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares.Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint.The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALMR":"Alamar Biosciences, Inc.","SPCX":"SPAC and New Issue ETF","IPOS":"Renaissance International IPO ETF"},"translate_title":"Alamar Biosciences将IPO规模定为940万股，每股定价为15-17美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMR":1.5,"SPCX":1.5,"IPOS":1.5},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Alamar Biosciences on Thursday said it plans to sell nearly 9.4 million shares at between $15 and $17 apiece in its initial public offering. \n\n\n  At the $16 midpoint of that range, the Fremont, Calif., proteomics company  said it expects net proceeds of about $133.2 million, or roughly $154.1 million if the underwriters exercise an option to buy an additional 1.41 million shares. \n\n\n  Alamar said it would have about 66.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization of roughly $1.06 billion at the $16-a-share pricing midpoint. \n\n\n  The company said it has applied to list its shares on the Nasdaq Global Select Market under the symbol ALMR. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2026 10:41 ET (14:41 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}